Is CTNM or PHVS more profitable?

Contineum Therapeutics' return on equity of -27.09% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -27.09% -25.64% Pharvaris N/A -67.56% -61.13%

Does the media prefer CTNM or PHVS?

In the previous week, Contineum Therapeutics and Contineum Therapeutics both had 2 articles in the media. Contineum Therapeutics' average media sentiment score of 1.43 beat Pharvaris' score of 0.52 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OCUL or CTNM?

In the previous week, Ocular Therapeutix had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 4 mentions for Ocular Therapeutix and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat Ocular Therapeutix's score of 0.86 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CTNM or ABCL?

In the previous week, AbCellera Biologics had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 4 mentions for AbCellera Biologics and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat AbCellera Biologics' score of 0.70 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ZLAB or CTNM?

In the previous week, Zai Lab had 4 more articles in the media than Contineum Therapeutics. MarketBeat recorded 6 mentions for Zai Lab and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat Zai Lab's score of 0.95 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Contineum Therapeutics (CTNM) Competitors

$14.62 -0.57 (-3.75%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$14.62 0.00 (-0.03%)

As of 07/13/2026 04:25 PM Eastern

Compare

CTNM vs. PHVS, OCUL, ABCL, HRMY, and ZLAB

Should you buy Contineum Therapeutics stock or one of its competitors? MarketBeat compares Contineum Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Contineum Therapeutics include Pharvaris (PHVS), Ocular Therapeutix (OCUL), AbCellera Biologics (ABCL), Harmony Biosciences (HRMY), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry.

How does Contineum Therapeutics compare to Pharvaris?

Contineum Therapeutics (NASDAQ:CTNM) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Contineum Therapeutics' return on equity of -27.09% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
Pharvaris	N/A	-67.56%	-61.13%

Contineum Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Pharvaris has a beta of -2.34, suggesting that its stock price is 334% less volatile than the broader market.

Contineum Therapeutics currently has a consensus target price of $20.00, indicating a potential upside of 36.80%. Pharvaris has a consensus target price of $49.64, indicating a potential upside of 41.54%. Given Pharvaris' stronger consensus rating and higher possible upside, analysts plainly believe Pharvaris is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Contineum Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	10.93	-$59.98M	-$1.95	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

In the previous week, Contineum Therapeutics and Contineum Therapeutics both had 2 articles in the media. Contineum Therapeutics' average media sentiment score of 1.43 beat Pharvaris' score of 0.52 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Contineum Therapeutics beats Pharvaris on 8 of the 11 factors compared between the two stocks.

How does Contineum Therapeutics compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Contineum Therapeutics (NASDAQ:CTNM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Contineum Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	41.64	-$265.94M	-$1.46	N/A
Contineum Therapeutics	$50M	10.93	-$59.98M	-$1.95	N/A

Ocular Therapeutix presently has a consensus target price of $25.11, suggesting a potential upside of 154.16%. Contineum Therapeutics has a consensus target price of $20.00, suggesting a potential upside of 36.80%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, equities research analysts plainly believe Ocular Therapeutix is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Contineum Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Contineum Therapeutics' return on equity of -27.09% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Contineum Therapeutics	N/A	-27.09%	-25.64%

59.2% of Ocular Therapeutix shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Ocular Therapeutix has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

In the previous week, Ocular Therapeutix had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 4 mentions for Ocular Therapeutix and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat Ocular Therapeutix's score of 0.86 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ocular Therapeutix beats Contineum Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Contineum Therapeutics compare to AbCellera Biologics?

Contineum Therapeutics (NASDAQ:CTNM) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

In the previous week, AbCellera Biologics had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 4 mentions for AbCellera Biologics and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat AbCellera Biologics' score of 0.70 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Contineum Therapeutics has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	10.93	-$59.98M	-$1.95	N/A
AbCellera Biologics	$75.13M	26.50	-$146.41M	-$0.48	N/A

Contineum Therapeutics presently has a consensus price target of $20.00, indicating a potential upside of 36.80%. AbCellera Biologics has a consensus price target of $8.00, indicating a potential upside of 22.70%. Given Contineum Therapeutics' higher possible upside, research analysts plainly believe Contineum Therapeutics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Contineum Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Contineum Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

61.4% of AbCellera Biologics shares are owned by institutional investors. 7.9% of Contineum Therapeutics shares are owned by insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

AbCellera Biologics beats Contineum Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Contineum Therapeutics compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Contineum Therapeutics (NASDAQ:CTNM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Harmony Biosciences has a net margin of 16.20% compared to Contineum Therapeutics' net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Contineum Therapeutics	N/A	-27.09%	-25.64%

In the previous week, Contineum Therapeutics had 1 more articles in the media than Harmony Biosciences. MarketBeat recorded 2 mentions for Contineum Therapeutics and 1 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.91 beat Contineum Therapeutics' score of 1.43 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Harmony Biosciences	Very Positive
Contineum Therapeutics	Positive

Harmony Biosciences has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.37	$158.69M	$2.48	14.33
Contineum Therapeutics	$50M	10.93	-$59.98M	-$1.95	N/A

Harmony Biosciences has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

86.2% of Harmony Biosciences shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by company insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Harmony Biosciences currently has a consensus price target of $42.50, indicating a potential upside of 19.58%. Contineum Therapeutics has a consensus price target of $20.00, indicating a potential upside of 36.80%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Harmony Biosciences beats Contineum Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Contineum Therapeutics compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Contineum Therapeutics (NASDAQ:CTNM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Contineum Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	4.85	-$175.54M	-$1.62	N/A
Contineum Therapeutics	$50M	10.93	-$59.98M	-$1.95	N/A

Zai Lab currently has a consensus price target of $40.00, indicating a potential upside of 103.87%. Contineum Therapeutics has a consensus price target of $20.00, indicating a potential upside of 36.80%. Given Zai Lab's stronger consensus rating and higher possible upside, equities research analysts plainly believe Zai Lab is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Contineum Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
Contineum Therapeutics	N/A	-27.09%	-25.64%

41.7% of Zai Lab shares are held by institutional investors. 4.9% of Zai Lab shares are held by company insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Zai Lab had 4 more articles in the media than Contineum Therapeutics. MarketBeat recorded 6 mentions for Zai Lab and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat Zai Lab's score of 0.95 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zai Lab has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Summary

Zai Lab beats Contineum Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Contineum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTNM vs. The Competition

Export

Metric	Contineum Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$567.90M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-7.50	20.85	27.13	24.26
Price / Sales	10.93	314.01	589.11	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	2.09	8.49	10.77	6.29
Net Income	-$59.98M	$23.83M	$3.58B	$330.66M
7 Day Performance	0.41%	-3.56%	-2.10%	-1.32%
1 Month Performance	23.06%	6.31%	3.29%	-0.64%
1 Year Performance	291.96%	48.30%	26.34%	19.08%

Contineum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTNM Contineum Therapeutics	1.9547 of 5 stars	$14.62 -3.8%	$20.00 +36.8%	+273.0%	$567.90M	$50M	N/A	31	News Coverage Positive News
PHVS Pharvaris	3.8693 of 5 stars	$34.23 -1.0%	$49.64 +45.0%	+39.6%	$2.23B	N/A	N/A	30
OCUL Ocular Therapeutix	3.2082 of 5 stars	$10.13 -1.9%	$25.11 +147.8%	-10.4%	$2.21B	$51.95M	N/A	230
ABCL AbCellera Biologics	2.3507 of 5 stars	$7.18 -6.7%	$8.33 +16.1%	+62.6%	$2.19B	$75.13M	N/A	500	Gap Down
HRMY Harmony Biosciences	4.7522 of 5 stars	$37.72 -1.4%	$41.44 +9.9%	+4.5%	$2.18B	$868.45M	15.20	200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTNM) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Contineum Therapeutics (CTNM) Competitors

CTNM vs. PHVS, OCUL, ABCL, HRMY, and ZLAB

How does Contineum Therapeutics compare to Pharvaris?

Summary

How does Contineum Therapeutics compare to Ocular Therapeutix?

Summary

How does Contineum Therapeutics compare to AbCellera Biologics?

Summary

How does Contineum Therapeutics compare to Harmony Biosciences?

Summary

How does Contineum Therapeutics compare to Zai Lab?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM vs. The Competition

Contineum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Contineum Therapeutics (CTNM) Competitors

CTNM vs. PHVS, OCUL, ABCL, HRMY, and ZLAB

How does Contineum Therapeutics compare to Pharvaris?

Is CTNM or PHVS more profitable?

Which has more volatility and risk, CTNM or PHVS?

Do analysts recommend CTNM or PHVS?

Which has preferable valuation & earnings, CTNM or PHVS?

Does the media prefer CTNM or PHVS?

Summary

How does Contineum Therapeutics compare to Ocular Therapeutix?

Which has stronger earnings & valuation, OCUL or CTNM?

Do analysts rate OCUL or CTNM?

Is OCUL or CTNM more profitable?

Do institutionals & insiders have more ownership in OCUL or CTNM?

Which has more volatility and risk, OCUL or CTNM?

Does the media favor OCUL or CTNM?

Summary

How does Contineum Therapeutics compare to AbCellera Biologics?

Does the media prefer CTNM or ABCL?

Which has preferable earnings and valuation, CTNM or ABCL?

Do analysts prefer CTNM or ABCL?

Which has more risk & volatility, CTNM or ABCL?

Is CTNM or ABCL more profitable?

Do institutionals and insiders believe in CTNM or ABCL?

Summary

How does Contineum Therapeutics compare to Harmony Biosciences?

Is HRMY or CTNM more profitable?

Does the media favor HRMY or CTNM?

Which has better valuation & earnings, HRMY or CTNM?

Which has more risk & volatility, HRMY or CTNM?

Do institutionals & insiders believe in HRMY or CTNM?

Do analysts recommend HRMY or CTNM?

Summary

How does Contineum Therapeutics compare to Zai Lab?

Which has better valuation & earnings, ZLAB or CTNM?

Do analysts rate ZLAB or CTNM?

Is ZLAB or CTNM more profitable?

Do institutionals and insiders hold more shares of ZLAB or CTNM?

Does the media prefer ZLAB or CTNM?

Which has more risk and volatility, ZLAB or CTNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM vs. The Competition

Contineum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools